1. Global Portfolio of Antimalarial Medicines
Translational
Product development
Access
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Approved/ ERP
Preclinical ▲
SAR121
Sanofi
M5717
Merck KGaA
P218
Janssen (Biotec Thailand)
Artefenomel/
Ferroquine
Sanofi
Tafenoquine
GSK/MMV
GSK/US Army
Arterolane-
piperaquine
Sun Pharma
Artemether-
lumefantrine
Various Manufactures 1
AN13762
MMV253
Zydus Cadila
SJ733
Kentucky/Eisai
KAF156/
Lumefantrine
Novartis
Dihydroartemisinin- piperaquine
dispersible
Alfasigma/Pierre Fabre
Rectal artesunate
Strides
Artemether-
lumefantrine
Dispersible
Various Manufacturers 3 2
UCT943
H3D Cape Town
SC83288
Heidelberg University
ACT
Actelion
Cipargamin
Novartis
Co-trimoxazole
ITM Antwerp
Artesunate
for Injection
Guilin 3
NPC1161B
Mississippi
CDRI 9778
Ipca
DSM265
Takeda
(UTSW)
Artemisinin-
naphthoquine
Kunming Pharma Co ▲
DM1157
DesignMedix
Dihydroartemisinin- piperaquine
Various manufacturers 4
MK4815
Merck
N-tert butyl Isoquine
LSTM/Liverpool/GSK
Fosmidomycin Piperaquine
Jomaa Pharma/GmbH
Artemether sub-lingual spray
MRC/Suda
Pyronaridine-
Artesunate Shin Poong 5
Methylene Blue/ amodiaquine
Heidelberg
Sulfadoxine-
pyrimethamine+
Amodiaquine dispersible S Kant
Pyronaridine-
artesunate granules
Shin Poong 5 6
SAR97276
Sanofi
Artesunate-
amodiaquine
Various Manufacturers 6
Artemisone
UHKST
Artesunate-
mefloquine
Cipla
AQ13
Immtech
Sulfadoxine-
pyrimethamine+
amodiaquine*
Guilin 7
Sevuparin
Dilaforette
Sulfadoxine-
pyrimethamine+
amodiaquine **
Guilin 7
MMV048
(UCT)
Rectal artesunate
Cipla/WHO-TDR

2. Footnotes: Global Portfolio
Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.
Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal :187
Target Product Profiles
indicated by bars at the bottom of each compound box
Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to each compound in the translational portfolio
Burrows Burrows
et al., 2013 et al., 2017
Asexual blood stages (TCP-1,2) TCP-1
Relapse prevention (TCP-3a) TCP-3
Transmission reduction (TCP-3b) TCP-5
Chemoprotection (TCP- 4) TCP-4
3-day cure, artemisinin-based combination therapies
Combinations aiming at a new Single exposure radical cure (TPP-1)
Severe malaria treatment and pre-referral intervention
Intermittent/seasonal malaria chemoprevention
Products targeting prevention of relapse for P. vivax
There are currently no products in the development portfolio meeting the single-exposure chemoprotection (SEC) TPP-2
Additional Symbols on Global Portfolio
Brought into portfolio after approval; collaborations with DNDi
No progress report in the last two years
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Paediatric formulation
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Approved in several countries but not approved by WHO pre- qualification nor regulatory bodies who are ICH members or observers
Footnote for Generic names on Global Portfolio
1.  First approval: Novartis (Brand name: Coartem®).  Generics by Ajanta, Cipla, Ipca, Strides, Macleods, Mylan;
First approval:  Novartis (Brand name: Coartem® Dispersible). Generic by Ajanta;
Brand name: Artesun®;
Brand name: Eurartesim®;
Brand name: Pyramax® tablets and granules;
First approval fixed-dose combination: Sanofi/DNDi (Brand name: ASAQ Winthrop). Generics by Ajanta, Cipla, Guilin, Ipca, Strides;
Brand name: SPAQ-COTM; ▲
* For children 13 – 60 months; ** For infants 3 – 12 months.